Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: TinaK who wrote (2173)	7/26/1998 3:07:00 PM
From: Peter Singleton	Respond to of 4676

Tina, could you unpack your comment: <<2922 has nonantisense side effects which in a very small number of patients were serious and irreversible>> Thanks! Peter

To: TinaK who wrote (2173)	7/27/1998 12:55:00 AM
From: John Zwiener	Read Replies (1) \| Respond to of 4676

Tina, I'm only aware of the published phase 2 data in the press release (2302 in chron's disease). What data was talked about in meetings that was not put in a press release? You indicate it is better than Avakine, but with the limited data out so far, I think we can say it is roughly equivalent or a little less (though it may work on different cases of chrons than avakine) (also, the data is limited, so yes, it could end up being proven to be better than avakine). Is there additional data, interrim data that was discussed somewhere. Fill us in if there was.